
    
      All participants will receive a single dose of vaccine, and will be assessed for
      immunogenicity at baseline (pre-vaccination) and at 28 days post-vaccination.

      Safety data, including serious adverse events (SAEs) will be collected for Day 0 through Day
      28 post-vaccination.
    
  